Intellia Therapeutics Inc (NASDAQ:NTLA)’s share price shot up 5% during trading on Wednesday . The stock traded as high as $18.52 and last traded at $18.45, with a volume of 134,791 shares changing hands. The stock had previously closed at $17.57.

Several research firms recently commented on NTLA. Leerink Swann began coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They set a “market perform” rating and a $32.00 target price on the stock. Wedbush began coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 target price on the stock. Jefferies Group began coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They set a “hold” rating and a $33.00 target price on the stock. Finally, Credit Suisse Group AG began coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 target price on the stock.

In related news, Director Carl L. Gordon acquired 250,000 shares of the stock in a transaction dated Wednesday, May 11th. The stock was acquired at an average cost of $18.00 per share, with a total value of $4,500,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Bros. Advisors Lp Baker acquired 200,000 shares of the stock in a transaction dated Wednesday, May 11th. The shares were bought at an average cost of $18.00 per share, with a total value of $3,600,000.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.